Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of “Buy” from Analysts

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been given an average rating of “Buy” by the eight ratings firms that are currently covering the company, MarketBeat reports. Seven investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued ratings on the stock in the last year is $42.83.

A number of equities analysts have recently commented on the company. HC Wainwright assumed coverage on Dianthus Therapeutics in a report on Thursday, May 16th. They issued a “buy” rating and a $40.00 target price for the company. Cantor Fitzgerald assumed coverage on Dianthus Therapeutics in a research note on Thursday, June 27th. They set an “overweight” rating for the company. Jefferies Financial Group raised their price target on Dianthus Therapeutics from $22.00 to $39.00 and gave the stock a “buy” rating in a research note on Friday, March 22nd. Lifesci Capital raised Dianthus Therapeutics to a “strong-buy” rating in a research note on Tuesday, June 11th. Finally, Wedbush raised their price target on Dianthus Therapeutics from $33.00 to $38.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of DNTH. Tower Research Capital LLC TRC bought a new stake in Dianthus Therapeutics during the 4th quarter valued at $25,000. Citigroup Inc. purchased a new position in shares of Dianthus Therapeutics in the 3rd quarter valued at $53,000. Virtu Financial LLC purchased a new position in shares of Dianthus Therapeutics in the 1st quarter valued at $390,000. Hussman Strategic Advisors Inc. purchased a new position in shares of Dianthus Therapeutics in the 1st quarter valued at $630,000. Finally, StemPoint Capital LP purchased a new position in shares of Dianthus Therapeutics in the 1st quarter valued at $1,304,000. 47.53% of the stock is owned by institutional investors.

Dianthus Therapeutics Stock Performance

Shares of Dianthus Therapeutics stock opened at $28.97 on Friday. The stock has a market cap of $850.27 million, a price-to-earnings ratio of -4.97 and a beta of 1.89. The stock has a 50 day moving average price of $24.72 and a 200-day moving average price of $22.68. Dianthus Therapeutics has a one year low of $6.58 and a one year high of $33.77.

Dianthus Therapeutics (NASDAQ:DNTH) last announced its earnings results on Thursday, May 9th. The company reported ($0.54) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.11). The firm had revenue of $0.87 million during the quarter, compared to analysts’ expectations of $0.48 million. Sell-side analysts predict that Dianthus Therapeutics will post -2.18 earnings per share for the current fiscal year.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.